1557241-91-4

Basic information

• Product Name: N,N-dimethyl-2-(4-nitro-1H- pyrazol-1-yl)-2-phenylethan-1-amine
• Synonyms: N,N-dimethyl-2-(4-nitro-1H- pyrazol-1-yl)-2-phenylethan-1-amine
• CAS NO: 1557241-91-4
• Molecular Weight: 260.296
• Mol File: 1557241-91-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N,N-dimethyl-2-(4-nitro-1H- pyrazol-1-yl)-2-phenylethan-1-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-dimethyl-2-(4-nitro-1H- pyrazol-1-yl)-2-phenylethan-1-amine(1557241-91-4)
• EPA Substance Registry System: N,N-dimethyl-2-(4-nitro-1H- pyrazol-1-yl)-2-phenylethan-1-amine(1557241-91-4)

Safety Data

• Hazardous Substances Data: 1557241-91-4(Hazardous Substances Data)

Upstream product

• 2075-46-9 4-nitro-1H-pyrazole 
• 6853-14-1 2-dimethylamino-1-phenylethanol 
• 96-09-3 styrene oxide 

Downstream Products

• 1557249-50-9 C₂₉H₄₄N₆O₂Si 

Relevant articles and documents

INHIBITOR COMPOUNDS

The present invention relates to compounds of Formula (I) that function as inhibitors of serum and glucocorticoid regulated kinase (SGK) activity: Formula (I) wherein X1, X2, Y1, Y2, Y3, Y4, R2, R3, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which SGK activity is implicated.

Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible t-cell kinase inhibitors

Interleukin-2 inducible T-cell kinase (ITK), a member of the Tec family of tyrosine kinases, plays a major role in T-cell signaling downstream of the T-cell receptor (TCR), and considerable efforts have been directed toward discovery of ITK-selective inhibitors as potential treatments of inflammatory disorders such as asthma. Using a previously disclosed indazole series of inhibitors as a starting point, and using X-ray crystallography and solubility forecast index (SFI) as guides, we evolved a series of tetrahydroindazole inhibitors with improved potency, selectivity, and pharmaceutical properties. Highlights include identification of a selectivity pocket above the ligand plane, and identification of appropriate lipophilic substituents to occupy this space. This effort culminated in identification of a potent and selective ITK inhibitor (GNE-9822) with good ADME properties in preclinical species.